Navigation Links
Halozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society of Clinical Oncology Annual Meeting
Date:5/15/2013

Halozyme. "We look forward to the study investigators presenting the updated study results at the poster session and ensuing discussion."

Based on the magnitude of response and safety observed in the Phase 1b study, Halozyme announced in April the initiation of a Phase 2 multicenter, randomized clinical trial evaluating PEGPH20 as a first-line therapy for patients with stage IV metastatic pancreatic cancer. Approximately 124 patients will participate in the study and receive gemcitabine and nab-paclitaxel either with or without PEGPH20. Secondary endpoints of the trial include clinical evaluation of patient response in both treatment arms by tumor biopsy hyaluronan (HA) status.

Halozyme is also developing a HA diagnostic tool that will help evaluate potential treatment benefit based on HA levels for use in the randomized Phase 2 trial. Clinically validating this HA-diagnostic approach in the pancreatic cancer trial may also provide proof-of-concept for use of PEGPH20 in other HA-rich tumor types.

Halozyme Abstracts at ASCO:

  • Poster Presentation/Discussion: (E Hall D1): "A Phase 1b Study of Gemcitabine Plus PEGPH20 (PEGylated Recombinant Human Hyaluronidase) in Patients with Stage IV Previously Untreated Pancreatic Cancer" will be presented by Sunil R. Hingorani M.D ., Ph.D., Fred Hutchinson Cancer Research Center on Monday, June 3 at 1:15PM-5:15PM CDT; discussion from 4:45 PM-5:45PM CDT. (Abstract #4010)
  • Educational Book Abstract: "Pharmacokinetic (PK)/Pharmacodynamic (PD) Results From a Phase 1b Study of PEGylated Hyaluronidase PH20 (PEGPH20) in Combination with Gemcitabine (Gem) in Patients with Pancreatic Cancer" (Abstract # e15005)

*33 percent response rate reported in the ASCO abstract based on partial data available at the time of abstract submission.

About Pancreatic Cancer
In most patients diagnosed with metastat
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Halozyme Therapeutics to Present at the 30th Annual J.P. Morgan Healthcare Conference
2. Halozyme to Host Fourth Quarter and 2011 Year-End Financial Results Conference Call
3. Halozyme Therapeutics to Present at Two Upcoming Investor Conferences in March
4. Halozyme to Host Second Quarter Financial Results Conference Call
5. Halozyme to Host Fourth Quarter and 2012 Year-End Financial Results Conference Call
6. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
7. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
8. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
9. Chimerix Announces Late-Breaking Poster Presentation at Kidney Week 2011 Annual Meeting
10. Pharmasset to Present at the Lazard Capital Markets Healthcare Conference
11. Masimo to Present at 23rd Annual Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... More than 5 million Americans are ... 3 seniors will die with Alzheimer’s or another dementia, ... have shocked many Americans into looking for ways to ... tragic age-related cognitive disorders. Jonathan Weisman, president of Biohack ...
(Date:1/15/2014)... Freeslate, Inc ., the leading ... Lupin Limited, one of India’s top five pharmaceutical companies, ... System for high throughput solid form screening. ... a wide range of quality, affordable generic and branded ...
(Date:1/14/2014)... January 14, 2014 Histogen, Inc., a ... of cells grown under simulated embryonic conditions, today announced ... with Suneva Medical, Inc. for physician-dispensed aesthetic products containing ... , This agreement is an amendment to the existing ...
(Date:1/14/2014)... DIEGO and BETHESDA, Md. ... are joining together with two institutes from the National ... reliable tools for bringing safer, more effective treatments to ... the National Center for Advancing Translational Sciences (NCATS) and ...
Breaking Biology Technology:Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
... (OTC Bulletin Board: WDST ) ( www.Regenicin.com ... Christopher A. Hadsall, whose primary responsibilities will be to ... as Chief Operating Officer.  Mr. Hadsall brings 12 years ... instrumental in working with various military groups to build ...
... Texas, Oct. 5 C3i, the leader in technology ... (BMS), a leading global biopharmaceutical company, will deliver a ... the newest version of Oracle Clinical/Remote Data Capture (OCRDC) ... the Oracle Health Sciences User Group conference (OHSUG) in ...
... Technologies, Inc. (ISTO), an  orthobiologics company with a cell-based ... patient enrollment in the Phase I clinical study for ... designed for the treatment of discogenic back pain. The ... All patients enrolled in the trial suffered from persistent ...
Cached Biology Technology:Regenicin Names Former U.S. Marine Corp Operations Officer, Christopher Hadsall, Chief Operating Officer 2Regenicin Names Former U.S. Marine Corp Operations Officer, Christopher Hadsall, Chief Operating Officer 3C3i and Bristol-Myers Squibb to Discuss the Effects of Oracle Clinical 4.5.3 Zero Footprint on Support Services at the Oracle Health Sciences User Group Conference 2ISTO Technologies, Inc., Completes Enrollment in Phase I NuQu Clinical Trial 2ISTO Technologies, Inc., Completes Enrollment in Phase I NuQu Clinical Trial 3
(Date:4/20/2014)... Stem cells the body,s master cells demonstrate ... level, according to a study published today from scientists ... as auxeticity is one which may have application ... Most materials when stretched will contract. For example, if ... will get thinner. The opposite is also true: squeeze ...
(Date:4/20/2014)... pancreatic cancers also promote drug-resistance and ultimately spur tumor ... School of Medicine have discovered a molecule, or biomarker, ... appears responsible for inducing tumor metastasis by enhancing the ... findings, published in the April 20, 2014 online issue ... new therapeutic opportunities for reversing drug resistance in a ...
(Date:4/20/2014)... Although doctors have long known that people with Down ... leukemia (ALL) during childhood, they haven,t been able to ... Institute investigators has uncovered a connection between the two ... the journal Nature Genetics , the researchers track ... abnormality in Down syndrome to the cellular havoc that ...
Breaking Biology News(10 mins):Bulletproof nuclei? Stem cells exhibit unusual absorption property 2Cancer stem cells linked to drug resistance 2Dana-Farber researchers uncover link between Down syndrome and leukemia 2Dana-Farber researchers uncover link between Down syndrome and leukemia 3
... key step toward providing patients with treatments based on their ... Genomics Consortium (IGC) have launched a new joint venture that ... Called Paradigm, the new nonprofit company brings together the expertise ... using genetic information to understand and treat disease. Beginning ...
... Aug. 16, 2012 Reportlinker.com announces that ... in its catalogue: Booming ... http://www.reportlinker.com/p0946283/Booming-CCTV-Market-in-Asia-Forecast-to-2014.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Security_Systems ... market has been experiencing significant growth due ...
... Aug. 15, 2012 DNA sequencing is rapidly getting faster ... patients will be able to use this information. In ... from around the world are vying to interpret the ... cause remains a mystery—with the goal of establishing "best ...
Cached Biology News:Creating a future of personalized medicine: U-M forms joint venture for DNA diagnostics 2Booming CCTV Market in Asia Forecast to 2014 2Booming CCTV Market in Asia Forecast to 2014 3Thirty teams compete to interpret three families' genomes 2Thirty teams compete to interpret three families' genomes 3Thirty teams compete to interpret three families' genomes 4Thirty teams compete to interpret three families' genomes 5
Standard and modified oligonucleotides up to 150 nt-long at any scale for broad applications. Price starts from 30p/base (10 nmole scale)....
... Extracts are optimized for maximum packaging efficiencies ... high efficiency extracts (> 109 pfu/g with ... a library containing at least 5 ... extracts are made from a specially designed ...
... Panorama Mouse/Rat Tissue Extract Protein Array Kit ... various tissue extracts. The expression of a ... a protein specific antibody. When the antibody ... by a sensitive chemiluminescent or fluorescent signal ...
... offers pre-validated SNP sequencing ... amplicons within 93 genes ... and more than 80 ... assays were developed and ...
Biology Products: